CellMax Life – Finding Cancer Early With Clinically Proven, Affordable Blood Tests – enabled by proprietary Circulating Tumor Cell platform | Taiwan-Healthcare+ Expo
Home     About Us     Medic-All     Bio B2B     Hot Topic     Expo     Login | Join Now     Search Button

CellMax Life – Finding Cancer Early With Clinically Proven, Affordable Blood Tests – enabled by proprietary Circulating Tumor Cell platform

2018-05-09

CellMax Life is a leading cancer diagnostics company whose mission is to transform how cancer is diagnosed and managed with globally affordable non-invasive tests across the continuum of care from early cancer detection, to treatment selection and monitoring.

 
Early cancer detection

CellMax’s Circulating Tumor Cell platform “CMx®” is a proprietary platform with exquisite sensitivity to detect rare circulating tumor cells (CTCs), such as those present in early cancer development or recurrence, when cancer cells may be present at less than 1-10 CTCs among 1 billion normal cells. This platform has 8 patents, and 36 publications and abstracts for applications ranging from early cancer detection, to treatment selection, and recurrence prediction. The CTC platform comprises a proprietary biomimetic membrane-coated microfluidic chip, proprietary antibodies, and a gentle air foam release mechanism enabling a CTC capture rate of >90% across all stages of cancer.
 

The CellMax CTC blood test for Colorectal Cancer was the only diagnostic test showcased by the American Society of Clinical Oncology (ASCO) conferences in 2018 from among 1000s of submitted abstracts. In a prospective study of 620 patients, the CRC test showed an accuracy of 84-88% for the detection of early stage cancer and pre-cancer. The ASCO GI expert Nancy Baxter commended the test for its simplicity and performance. This affordable blood test can increase testing compliance, and help detect cancer early when the survival rates are >90%. The CTC platform can be used across all solid tumors.

 

Data on the CellMax CTC blood test for prostate cancer was selected for an oral presentation at the 2018 American Urology Association meeting –the largest urology meeting in the world- as well as 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Meeting. The study included 200 PSA gray zone patients. For these patients, CellMax Life's screening had an 80% sensitivity and over 90% specificity for early prostate cancers showing the potential to reduce the number of unnecessary prostate biopsies in these patients significantly. This is important given the costs, complications (33% rate), and false positive rates (80%) of biopsies in this population.

CellMax Life has also developed a proprietary Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) technologies.

 
Cancer risk assessment

CellMax’s next generation sequencing technology expertise enables the most comprehensive, affordable home test for hereditary cancer risk assessment of 25 cancers. The clinical utility of multi-gene testing, including but not limited to BRCA1 and 2, in high as well as average risk patients is now well published. Patients with these mutations can take proactive measures such as earlier and more frequent screening to potentially prevent cancer or detect cancer early when it is most treatable.

Personalized Cancer Therapy Selection (Targeted Therapy plus Immunotherapy) and Treatment Monitoring –

CellMax Life circulating tumor DNA (ctDNA) technologies has best in class sensitivity and specificity for the detection of genomic alterations and MSI. The performance data of this test was presented at the American Association of Cancer Research in April 2018

CellMax Life's liquid biopsy analyzes both CTC and ctDNA for genomic alterations, MSI, and Protein expression, all from a single blood sample.

It is the first and only blood test to complete in its coverage of all biomarkers recommended in the National Comprehensive Cancer Network (NCCN) guideline for solid tumor Immunotherapy and Targeted therapy selection.

 

CellMax Life’s PD-L1 CTC blood test can be used as a basis for precision targeted therapy as well as evaluation of drug efficacy. The results showed that the sensitivity of screening early-stage lung cancer with PD-L1 is as high as 90%. For patients with advanced lung cancer, about 50% tested positive for PD-L1 and the sensitivity is consistent with the clinical study. The test can help doctors to select drugs precisely in the future. For patients with solid tumors for whom tissue biopsies are difficult to obtain, the test may be the best solution outside of tissue testing, helping late-stage patients choose immunotherapy and targeted therapy drugs. The research was presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.


At this year's Taiwan Healthcare+ Expo, CellMax Life will focus on boosting its promotion and collaboration with hospitals in personalized targeted therapy and diagnostics products. In addition, CellMax Life will expand its early-stage cancer diagnostics business in New Zealand, Australia, South East Asia, North Asia, and regional markets in the Middle East by cooperating with local distributors.

 

Category Product and Service
Early detection and Screening of cancer
  • DNA genetic risk test
  • CRC protect™
  • Prostate Cancer Test™
Personalized Targeted Therapy Selection
  • CellMax Liquid biopsy
  • CTC-based PD-L1 assay
Recurrence Monitoring
  • CRC Monitor™
  • PanCA Monitor™

 

(Editing by Jim Shih, Research Center for Biotechnology and Medicine Policy)